SCHEMBL1200246

SCHEMBL1200246

O=Cc1ccccc1OS(=O)(=O)c1ccccc1[N+](=O)[O-]

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 6/20 0.63
SMN1; SMN2 Q16637 2/20 0.63
KMT2A Q03164 8/20 0.60
MEN1 O00255 7/20 0.60
ALDH1A1 P00352 7/20 0.60
POLB P06746 1/20 0.60
GSK3B P49841 1/20 0.58
MAPT P10636 2/20 0.46
ERN1 O75460 1/20 0.45
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
MMP1 P03956 1/20 0.44
MMP2 P08253 1/20 0.44
MMP9 P14780 1/20 0.44
MMP8 P22894 1/20 0.44
MMP13 P45452 1/20 0.44
ACHE P22303 1/20 0.43
LMNA P02545 1/20 0.43
TDP1 Q9NUW8 1/20 0.41
F2 P00734 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11134429 0.85 KMT2A (0.59) HPGDSMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL6749821 0.79 KMT2A (0.53) HPGDSMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL11628678 0.79 KMT2A (0.53) HPGDSMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL1200410 0.78 ALDH1A1 (0.69) HPGDSMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL27854884 0.77 MAPT (0.67) HPGDSMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL3154729 0.76 ALDH1A1 (0.55) HPGDSMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL4111651 0.75 HPGD (0.60) HPGDSMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL11543322 0.75 KMT2A (0.59) HPGDSMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL999377 0.74 KMT2A (0.68) HPGDKMT2AMEN1ALDH1A1POLB
SCHEMBL8014864 0.74 KMT2A (0.68) HPGDKMT2AMEN1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2154123-B1 METHOD FOR PRODUCING BENZALDEHYDE COMPOUND SUMITOMO CHEMICAL CO (JP) 2013-10-23 EP disclosed
CN-101679171-B Method for producing benzaldehyde compound SUMITOMO CHEMICAL CO 2012-12-12 CN disclosed
US-8309753-B2 Method for producing optically active cyanohydrin compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-11-13 US disclosed
US-20110034718-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-02-10 US disclosed
EP-2264005-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND Sumitomo Chemical Company, Limited (JP) 2010-12-22 EP disclosed
US-7851659-B2 Method for producing benzaldehyde compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-12-14 US disclosed
US-20100234645-A1 METHOD FOR PRODUCING BENZALDEHYDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-09-16 US disclosed
CN-101679171-A Method for producing benzaldehyde compound SUMITOMO CHEMICAL CO 2010-03-24 CN disclosed
EP-2154123-A1 METHOD FOR PRODUCING BENZALDEHYDE COMPOUND Sumitomo Chemical Company, Limited (JP) 2010-02-17 EP disclosed
EP-1845083-A2 New arylsulfonohydrazide inhibitors of enzymes MurC and MurD UNIVERZA V LJUBLJANI, FAKULTETA ZA FARMACIJO (SI) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234645-A1 METHOD FOR PRODUCING BENZALDEHYDE COMPOUND NQO1, NQO2, NDUFC2 HPGD 564/4885SMN1; SMN2 4324/4885KMT2A 548/4885
US-20110034718-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND CBR3, ACSL3, CCNL2 HPGD 1408/4885SMN1; SMN2 2884/4885KMT2A 1113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.